Tempest Therapeutics (TPST)

• Market cap: $29M
• 1 day: -6.05%
• 5 days: 16.09%
• 1 month: 27.04%
• 3 months: -15.83%
• 6 months: -78.83%
• Year to date: -31.53%
• 1 year: -69.72%
• 5 years: -99.07%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Employees: 4